The healthcare business continues to develop at a fast tempo with diagnostic companies taking part in an necessary function on this house. Girls’s well being diagnostic firm Sera Prognostics is about to go public this week and listed below are a couple of factors to notice concerning the transaction:
Sera Prognostics is scheduled to go public on Thursday, July 15. The corporate is predicted to start buying and selling on NASDAQ below the ticker image SERA. Sera will provide 4.7 million shares at a worth vary of $15-17 per share to boost $75 million. The IPO might be managed by Citigroup, Cowen and William Blair.
Sera Prognostics develops diagnostic checks that assist predict dangers related to being pregnant resembling untimely supply. The corporate makes use of its proteomics and bioinformatics platform to find protein biomarkers in blood that may predict dynamic adjustments throughout being pregnant. This information helps in predicting varied pregnancy-related issues resembling the danger of a preterm beginning. This can assist in considerably enhancing maternal and neonatal well being.
Sera’s product, the PreTRM take a look at, is the one commercially out there blood-based biomarker take a look at that helps in precisely predicting the danger of a untimely supply. It’s a non-invasive blood take a look at given to pregnant ladies throughout weeks 19 or 20 of gestation that predicts the danger of the mom delivering spontaneously earlier than 37 weeks.
Sera has a collaboration with well being insurer Anthem Inc. (NYSE: ANTM) below which Anthem will make the PreTRM take a look at out there to eligible pregnant members as a part of a multi-year contract. Anthem has greater than 43 million members and its well being plans cowl over 10% of pregnancies within the US yearly. Sera believes this alliance will de-risk preliminary commercialization and pave the way in which for broader market adoption for its PreTRM take a look at.
Sera generated revenues of $25,000 in FY2020. The corporate delivered a web lack of $19.8 million throughout the identical interval. The corporate was based in 2008 and has 76 staff.
There are approx. 140 million births worldwide every year of which round 25% are affected by varied issues resembling preterm beginning, preeclampsia, fetal progress restriction, stillbirth and gestational diabetes amongst others. Within the US alone, there are round 3.8 million births yearly and over 10% of those pregnancies end in preterm beginning with profound well being penalties to the mom and child.
These well being penalties are estimated to result in prices of approx. $25 billion yearly within the US. Sera believes its biomarker checks may help mitigate the issues related to untimely beginning in addition to scale back healthcare prices.
Click on right here to learn extra IPO tales